Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VMD-102 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on VMD-102, a putative PKC epsilon inhibitor (Jun 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VMD-102 | VMD102|VMD 102 | Limited information is currently available on VMD-102, a putative PKC epsilon inhibitor (Jun 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07636785 | Phase Ib/II | VMD-102 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors (Pro-KCEI) | Not yet recruiting | USA | 0 |